Research Article

Assessment of Vitamin D-Binding Protein and Early Prediction of Nephropathy in Type 2 Saudi Diabetic Patients

Table 2

Laboratory parameters of the study groups.

VariablesControl group ()Diabetic groups values
Normal albuminuriaMicroalbuminuriaMacroalbuminuria
()()()

Lipid profile
Total cholesterol (mmol/l)4.8 ± 1.54.8 ± 0.74.6 ± 0.95.1 ± 1.40.289
HDL-c (mmol/l)1.2 ± 0.41.2 ± 0.31.1 ± 0.40.9 ± 1.00.196
LDL-c (mmol/l)6.9 ± 24.53.3 ± 0.63.4 ± 1.11.12 ± 0.40.417
Total triglyceride (mmol/l)1.3 ± 0.81.7 ± 0.81.4 ± 0.52.7 ± 0.9 b c<0.001
Diabetic assessment
FBS (mmol/l)5.5 ± 5.97.9 ± 5.312.1 ± 16.7a11.8 ± 4.1a,b0.004
HbA1c (%)4.7 ± 0.47.2 ± 0.7a7.5 ± 1.4a9.4 ± 0.8a,b,c<0.001
Fasting insulin (mIU/l)9.6 ± 5.025.3 ± 10.4a32.3 ± 14.4a,b37.8 ± 16.8a,b<0.001
HOMA-IR index0.15 ± 0.250.8 ± 1.2a0.4 ± 0.3b0.7 ± 0.4a<0.001
Total protein (gm/l)74.2 ± 10.473.9 ± 3.270.7 ± 4.271.9 ± 5.50.052
Serum albumin (gm/l)47.7 ± 7.735.0 ± 3.3a34.1 ± 2.4a34.4 ± 2.5a<0.001
Renal function tests
Serum urea (mmol/l)3.5 ± 1.14.6 ± 1.0a4.5 ± 0.9a4.5 ± 1.4a<0.001
Serum creatinine (μmol/l)57.7 ± 12.556.2 ± 16.059.1 ± 9.869.2 ± 16.6a,b,c<0.001
Albumin/creatinine ratio (μg/mg)16.7 ± 8.710.5 ± 7.877.5 ± 65.5803.5 ± 355a,b,c<0.001
eGFR (ml/min/1.73 m2)102.4 ± 17.6111.2 ± 36.6107.9 ± 17.2113.3 ± 22.90.232
Inflammatory markers
hs-CRP (mg/l)0.12 ± 0.080.17 ± 0.05a0.17 ± 0.04a0.15 ± 0.02a,b,c<0.001
VDBP analyses
sVDBP (μg/ml)210.3 ± 33.8202.4 ± 43.9248.4 ± 36.5a,b299.2 ± 50.6a,b,c<0.001
uVDBP/uCr (ng/mg)127.7 ± 21.9193.1 ± 141.0820.4 ± 402.8a,b1458.1 ± 210a,b,c<0.001

Data are expressed as mean ± SD. HDL: high-density lipoprotein cholesterol; LDL: low-density lipoprotein cholesterol; FBS: fasting blood sugar; HBA1c: hemoglobin A1c; HOMA: homeostasis model assessment; eGFR: estimated glomerular filtration rate; hs-CRP: high sensitivity C-reactive protein. aCompared to control group. bCompared to diabetic normal albuminuria group. cCompared to diabetic microalbuminuria group. Bold values indicate significance at .